Sort
21,453 grants matching “tuberculosis”
SBIR Phase I: Low cost portable system for the rapid detection and drug resistance profiling of Tuberculosis
$225,000Stephen D Oconnor · Impedx Diagnostics · · FY2016 · TIP
Development of an engineered CCL20 protein as a lead therapeutic molecule for Psoriasis
$224,999Anthony E Getschman · Protein Foundry, Llc · R43 · FY2018 · AR
Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA
$224,998Sean Ekins · Collaborations Pharmaceuticals, Inc. · R41 · FY2018 · AI
INNOVATIVE ORAL FORMULATIONS FOR ANTI-TB DRUGS
$224,997Blaine Butler · Luna Innovations, Inc. · N01 · FY2016 · AI
Cough sample collection and processing for the diagnosis of pulmonary TB
$224,981Stephen Chapman · Deton Corporation · R43 · FY2016 · HL
IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs
$224,960Lawrence Zisman · Pulmokine, Inc. · N43 · FY2013 · AI
TREATMENT OF TUBERCULOSIS WITH INHALED DELIVERY OF CLOFAZIMINE
$224,946Brian Hansen · Aerophase, Inc. · N43 · FY2015 · AI
Cell wall carbohydrate recycling in Mycobacterium tuberculosis
$224,943Mary Sloan Siegrist · University Of Massachusetts Amherst · R21 · FY2025 · AI
Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program
$224,940Sebastian Seiguer · Emocha Mobile Health, Inc. · R41 · FY2020 · DA
IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs
$224,916Ronnie Toddywala · · N43 · FY2013 · AI
Immune Modulation During Acute Lyme Disease Infection as the Result of Aberrant Immunoglobulin Glycosylation
$224,908Mary Ann Comunale · Drexel University · R21 · FY2023 · AI
Rapid Molecular Detection of Tuberculosis without PCR amplification
$224,890Alfredo Andres Celedon · Scanogen, Inc. · R43 · FY2016 · AI
SBIR Phase I: Ultra-sensitive Detection of Lipoarabinomannan (LAM) and Interferon-Gamma (IFN-g) as Biomarkers for Detection of Tuberculosis (TB)
$224,876Syed Barizuddin · Plasmonic Diagnostics Llc · · FY2018 · TIP
CAPREOMYCIN: FORMULATION FOR ORAL DELIVERY
$224,868Ada Cowan · Metallopharm, Llc · N43 · FY2014 · AI
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.
$224,839Jonah B. Sacha · Oregon Health & Science University · R21 · FY2016 · AI
Novel Medical Food for the Management of Iron Deficiency Anemia
$224,836Darren Wolfe · Sidero Bioscience, Llc · R41 · FY2016 · DK
Developing a Diagnostic Blood Test for Sarcoidosis
$224,780David Robert Moller · Sarcoidosis Diagnostic Testing, Llc · R41 · FY2015 · HL
Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath
$224,770Swomitra Kumar Mohanty · Nanosynth Materials And Sensors, Inc. · R41 · FY2015 · HL
A new pathway for azole resistance in Aspergillus fumigatus
$224,764W Scott Moye-Rowley · University Of Iowa · R21 · FY2015 · AI
Developing a POC CMOS biochip for oral HPV detection and quantification
$224,764Arjang Hassibi · Insilixa, Inc. · R43 · FY2015 · DE
A Wearable Monitoring Device Used for the Assessment of Patients with Chronic Respiratory Diseases
$224,746Patrick Allan Lichter · Koronis Biomedical Technologies Corporat · R43 · FY2018 · AG
Reinforcing old warriors to treat Mycobacterium kansasii in shorter duration
$224,742Shashi Kant · University Of Texas Hlth Ctr At Tyler · R21 · FY2020 · AI
Evolution of KPC-K pneumoniae that persist in patients on prolonged antibiotics
$224,737Cornelius J Clancy · University Of Pittsburgh At Pittsburgh · R21 · FY2015 · AI
Capreomycin Cochleates: Oral Formulation for Tuberculosis
$224,735Carl J Craft · Aquarius Biotechnologies, Inc. · N43 · FY2014 · AI
Lactoferrin Modulation of Granuloma Pathology
$224,725Jeffrey K Actor · Pharmareview Corporation · R41 · FY2015 · AI